The International Prognostic Scoring System and its revised form (IPSS-R) are the most widely used indices for prognostic assessment of patients with myelodysplastic syndromes (MDS), but can only partially account for the observed variation in patient outcomes. This study aimed to evaluate the relative contribution of patient condition and mutational status in peripheral blood when added to the IPSS-R, for estimating overall survival and the risk of leukemic transformation in patients with MDS. A prospective cohort (2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015) of 200 consecutive patients with MDS were included in the study series and categorized according to the IPSS-R. Patients were further stratified according to patient condition (assessed using the multidimensional Lee index for older adults) and genetic mutations (peripheral blood samples screened using next-generation sequencing). The change in likelihood-ratio was tested in Cox models after adding individual covariates.
| I N T R O D U C T I O N
Approximately 25% of the patients diagnosed with MDS die from progression to acute myeloid leukemia (AML), whereas the rest will have a non-leukemic death (NLD), including the 25% who die from MDSunrelated causes. 1 Since its publication in 1997, 2 the International Prognostic Scoring System (IPSS) has been the widest-used prognostic index in MDS patients, and a revised form (IPSS-R) was published in 2012. 3 The IPSS-R was derived from a large retrospective patient series, incorporates refined cytogenetic stratification 4 and takes into account depth of cytopenia. In addition, enumerating bone marrow blast from nonerythroid cellularity and using a unique cutoff of 3.5 has been shown to improve its prognostic performance. [5] [6] [7] However, neither the IPSS nor the IPSS-R have faced the problem of death from MDS-unrelated causes.
The term "patient condition" is defined here as the general status of the typically old MDS patient, assessed multidimensionally according to demographic, behavioral, nutritional, comorbid, and functional parameters. The Comprehensive Geriatric Assessment captures most of this factors; 8 however, many patients diagnosed with MDS are <65 years and cannot therefore be considered elderly, and the term "older adults" seems more appropriate. The 12-item Lee index 9 is one of the best-performing multidimensional prognostic indices for older adults, 10 used to predict 4-and 10-year mortality. 9, 11 Developed from a population of community-dwelling adults aged >50 years, the index incorporates age, gender, smoking habit, 12 body mass index, comorbidity, and functional performance into a single tool suitable for daily practice. A modification of this index predicts 5-year mortality. 13 Although it cannot substitute a Comprehensive Geriatric Assessment in the oldest adults, 14 the index has been adequately validated and can also be applied to patients aged between 50 and 65 years old.
Mutational analysis of bone marrow (BM) at diagnosis has been demonstrated to contribute to survival prediction, independently of the IPSS in several retrospective patient series [15] [16] [17] [18] and also, recently, independently of the IPSS-R in a prospective patient series. 19 There is however a lack of prospective studies analyzing the relative contribution of mutational status and patient condition to outcome prediction in patients already stratified according to the IPSS-R. Futhermore, mutational analysis of peripheral blood (PB) samples from MDS patients, a variant of the so-called "liquid biopsy," 20 has not been performed on a sufficiently large population of MDS patients. A template for a molecular upgrade of the IPSS-R ("IPSS-R molecular") derived from mutational analysis of BM data was recently proposed, 21 but did not take into account patient condition. In 2016, authors of the European Haematology Association Roadmap for European Hematology
Research concluded that studies analyzing the relationship between genotype, gender, age and comorbidities are required to improve the prognostic/predictive models for MDS. 22 The aim of this study was to evaluate the relative contribution of patient condition and mutational analysis in peripheral blood, as tools to improve the IPSS-R for estimating overall survival (OS) and the risk of leukemic transformation (LT) in MDS patients. Our hypothesis was that both of them may add prognostic information to the IPSS-R. Unprocessed PB samples collected at diagnosis from every patient at each study site was sent unprocessed at ambient temperature to a central facility for nucleic acid extraction and were kept frozen at 2808C until mutational analysis performed.
| M E T H O D S

| Patients and clinical methods
| Mutational analysis
The mutational analysis by next-generation sequencing (NGS) was carried out for the 159 (79.5%) patients whose DNA was of adequate quality, following procedures described elsewhere. 26 A list of genes analyzed in all patients is shown in Supporting Information Table S1 .
Given the difficulties to develop a robust molecular profile for outcomes prediction, the patients were instead stratified according to the modified score of Bejar et al. 21 In short, patients were stratified into 3 groups according to the presence/absence of mutations in the SF3B1 gene and the presence/absence of any mutations in the genes TP53, CBL, EZH2, RUNX1, U2AF1 or ASXL1; favorable: SF3B1 mutation only; unfavorable:
wildtype SF3B1 1 mutation in any of the other six genes; intermediate:
all other patients. All assays were performed blinded to the study end points, by technicians who were not involved in patient management. ). Cases with missing values in one covariate were excluded in all the tests where that covariate was used.
| Statistical analysis
OS was defined as the time from diagnosis to death (as a result of all causes), last follow-up or study closing date, and was plotted using the Kaplan-Meier product-limit method. Cumulative incidence of LT was calculated from diagnosis to progression to AML (>20% blast cells in PB or BM), last follow-up or closing date using the method described competing risk-was 11% (95% CI 9-16%), 19% (95% CI 14-27%) and 23% (95% CI 17-30%), respectively (Supporting Information Figure S2 ). taking into consideration the eventual presence of SF3B1 mutations in patients with 5-15% ring sideroblasts (Supporting Information Table S5 ).
| Mutational analysis
| Overall survival prediction
IPSS-R adequately predicted OS in univariate analysis in our series (HR 2.12, CI 95% 1.76-2.53, P < 0.001; Supporting Information Figure   S1b ), but Lee index and the mutational analysis according to the Bejar's 2015-modified molecular score also showed a statistically significant univariate impact ( Figure 2 and Table 1 ). The addition of Lee index to IPSS-R, significantly improved the model's prognostic power (as measured by the likelihood ratio test) whereas mutational analysis did not have such an effect ( Table 1 ). The increased discriminating power of the expanded prognostic models on OS compared with IPSS-R alone is shown in Supporting Information Table S6 .
Several "differentiating variables for survival" also added prognostic information for OS (although not for LT) independently of the IPSS-R but with lower adjusted HRs (Supporting Information Tables S7 and   S8 ). Furthermore, none of them improved significantly the prognostic power of the combination of IPSS-R and Lee index. More specifically, the addition of age to IPSS-R and Lee index did not significantly improve the prognostic power of the model (P 5 0.06).
| Prediction of leukemic transformation and non-leukemic death
Both IPSS-R (standardized hazard ratio [SHR] 2.23, 95% CI 1.75-2.84, P < 0.001) and mutational analysis (P < 0.001) could be used to predict cumulative incidence of LT by univariate analysis, whereas the Lee index could not (P 5 0.71) ( 9 In this study, the Lee index was categorized into three strata (score <6; 6-13; and >13)
Finally, adjustment of the above models for exposure to diseasemodifying therapeutic strategies had no effect on their prognostic power, as measured by changes in the HR (data not shown).
| Clinico-biological correlates
There was a significant correlation between the Lee index score, and ECOG PS and serum beta-2 microglobulin levels (rho 10.49, P < 0.001; and rho 10.42, P < 0.001; respectively), but not with the IPSS-R score (rho 20.13, P 5 0.061). In contrast, there was a significant association between IPSS-R category and both the original molecular score 12 and the modified molecular score 18 (P 5 0.004 and P 5 0.023, respectively; chi-squared for trend). We did not find any statistically significant association between patient condition and mutational status (P 5 0.28, Supporting Information Table S9 ). 
| DISCUSSION
In agreement with prospective studies published in 2016, we con- MDS is proposed (Figure 3 ).
Within the series, patient age was a predictor of shorter OS and a lower risk of LT, as assessed by univariate analysis. According to the data presented, NLD acted as a mediator for both, acting directly on the OS and behaving as a competing risk event for LT.
The IPSS-R and the WHO Classification-Based Prognosis Scoring System (WPSS) are used to predict both OS and LT across the whole spectrum of primary MDS. 3, 42, 43 In recent years, other prognostic scoring systems for patients with lower-risk MDS, 39, 40 as well as for patients with secondary and previously treated MDS, 41 have been published, most of which include age and/or ECOG PS as prognostic variables. We hypothesize that that incorporation of patient condition and mutational status in PB might also increase the prognostic power of these indices.
ECOG PS is one of the most commonly used covariates in prognostic models for cancer patients; however, it does not take into account comorbidity, which is also a relevant predictor of OS in patients with MDS. [33] [34] [35] [36] [37] [38] 44, 45 Comorbidity was not analyzed during IPSS or IPSS-R development, but was evaluated in later studies in retrospective cohorts. In our study, the multidimensional Lee index, categorized in three strata (score <6, 6-13, and >13) adequately predicted OS in a prospective cohort of MDS patients. Interestingly, the Lee index did not correlate with transfusion dependence whereas PS did.
This result could be related to the fact that the Lee index evaluates functional performance of patients prior to MDS diagnosis, whereas ECOG PS evaluates the functional impact of MDS itself.
An interesting observation from our data is the differential contribution of the patient condition and mutational analysis to prognosis assessment of patients with MDS. Although IPSS-R is a potent prognostic tool for OS, its effect appears to occur predominantly through its implication in LT, since in our hands it did not predict NLD (though : patients are stratified into three groups according to the presence/absence of mutations in the SF3B1 gene and the presence/absence of any mutations in the genes TP53, CBL, EZH2, RUNX1, U2AF1 or ASXL1. Those patients harboring only a mutation in SF3B1, but not in the other six genes are assigned to the the favorable group, those who have wildtype SF3B1 and a mutation in any of the other six genes are assigned to the unfavorable group, and the rest are allocated to the intermediate group. PB, Peripheral blood. HR, Hazard ratio. SHR, Standardized hazard ratio. CI 95%, Confidence interval 95%. Adjusted, refers to the values when introducing both IPSS-R and a single additional covariate in the model. IPSS-R categories used for the adjustment: Very low, Low, Intermediate, High, Very high.
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the problem of small numbers may be an issue). In our study, the Lee index improved the predictive power of the IPSS-R in terms of OS, through its power to predict NLD, thus overcoming mutational analysis in this regard.
Mutational analysis by NGS is a promising tool for MDS prognosis assessment and, when performed using PB, may be particularly useful in patients with prominent marrow fibrosis. 26 It is also an ideal tool for studying clonal evolution, especially in older and debilitated MDS patients who would otherwise require repeated BM punctures. In this study, mutational analysis was performed on DNA isolated from the whole cellular fraction of PB, replicating previously published data on the independent prognostic value of mutational analysis. Diseasemodifying therapeutic strategies may have acted as a potential confounding factor, 46-49 but after adjusting for it we did not detect any relevant change in the hazard and sub-hazard estimations.
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FIG URE 3
An integrative algorithm for predicting outcome of MDS patients. The treatment algorithm proposes: 1. The categorization of patients according to IPSS-R score (enumerating BM blasts from nonerythroid cellularity and using a unique IPSS-R cutoff of 3.5 has been shown to improve IPSS-R prognostic power) [5] [6] [7] ; 2. NGS mutational analysis of BM or peripheral blood (the technology is expected to improve over time with improved understanding of gene interactions); 3. Further categorization by the Lee index (other indices may also be used in daily practice 10, 11, 13, [33] [34] [35] [36] [37] [38] ). Other high-risk features include: severe neutropenia, severe thrombocytopenia, marrow fibrosis grade 2-3, high scores in other dedicated tools. 26, [39] [40] [41] The dashed line for patients with a Lee index score >13 indicates that this subset of patients might not obtain a definite survival benefit when treated by current therapeutic strategies, despite the prognostic significance of the Lee index score for OS. BM, bone marrow; IPSS-R, revised international prognostic scoring system; MDS, myelodysplastic syndromes; NGS, next-generation sequencing; OS, overall survival
